Exai Bio, a next-generation oncRNA- and generative AI-based liquid biopsy company, today announced a peer-reviewed ...

Biofidelity, a leader in innovative genomic solutions, today announced the launch of Aspyre Clinical Test for Lung for liquid biopsy samples. Aspyre Clinical Test for Lung analyzes all ...

Lung cancer treatment has witnessed a revolution in recent years, largely driven by the increasing understanding of genetics ...

The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for patients with metastatic non–small cell lung ...

"Our mission is to make cancer less deadly through widely accessible next-generation early detection blood tests." Susan Tousi, CEO of Delfi Diagnostics, tells Bloomberg Intelligence in this episode ...

CTC PD-L1 assay enables longitudinal monitoring of PD-L1 status in lung cancer patients and may help to advance personalised treatment GUILDFORD, UNITED KINGDOM / ACCESSWIRE / November 15, 2024 / ...

Cancer, one of the most life-threatening diseases, is projected to affect over 35 million people worldwide in 2050 — 77% more ...

2024 — Using artificial intelligence technology to identify patterns of DNA fragments associated with lung cancer, researchers have developed and validated a liquid biopsy that may help identify ...

The Guildford, England-based liquid biopsy company is presenting the new test results at the American Association for Cancer Research's Special Conference, 'Liquid Biopsy: From Discovery to Clinical ...

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday.